ANA971, an orally administered prodrug of isatoribine. Isatoribine is a nucleoside analog in development for the treatment of chronic hepatitis C virus (HCV) infection. ANA971 is a prodrug designed to... ANA971 resulted in higher levels of isatoribine in the blood than were present after oral administration of isatoribine itself.
- Mechanism
- Curator reviewed
The mechanism of action is the same as for isatoribine. Isatoribine is believed to act by a mechanism of action involving interaction with Toll-like receptor 7 (TLR7) and stimulation of the patient's own immune system, but the precise mechanism by which isatoribine reduced viral load is unknown (possible mechanisms include an antiviral effect, modulation of innate immunity, or enhancement of cellular responses).
- Primary indication
- Investigated for use/treatment in hepatitis (viral, C).Curator reviewed
- Code names
- ANA971
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with ANA971, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account